Clinical Trial: Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07714213) titled 'Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)' on July 15.

Brief Summary: Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog"), mood changes, and reduced quality of life. In some people, these symptoms continue for months or longer and can substantially affect daily activities. Currently, there are no approved treatments that specifically target these symptoms.

Aripiprazole is a medicine that is approved to treat certain psychi...